• News
  • BioTech

Halozyme stock dips on share offering

Shares in San Diego’s Halozyme Therapeutics (Nasdaq: HALO) dropped sharply on Wednesday after the company announced it was launching a new offering of 7.7 million shares priced at $13 per share, compared to Wednesday’s opening price of $13.55.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!